Modeling the prediction on the efficacy of a homologous third dose of coronavac against sars-cov-2 omicron ba.1, ba.2,

HIGHLIGHTS

• who: China CDC Weekly and collaborators from the Chinese Center for Disease Control and Prevention have published the research work: Modeling the Prediction on the Efficacy of a Homologous Third Dose of CoronaVac Against SARS-CoV-2 Omicron BA.1, BA.2,, in the Journal: (JOURNAL) of November/01,/2022

SUMMARY

October 1, 2022 October, the Omicron BA.5 subvariant has been observed in 139 countries across all six WHO regions and has become a globally dominant subvariant due to its Chinese Center for Disease Control and Prevention substantial growth advantages and faster . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.